MACS GMP CD3 pure is a GMP-grade soluble CD3 (OKT3) antibody for
ex vivo
T cell activation.
Disclaimer
MACS GMP Products are for research use and
ex vivo
cell culture processing only, and are not intended for human
in vivo
applications. For regulatory status in the USA, please contact your local representative.
Background information
The CD3 antibody (OKT3) recognizes the human CD3 antigen which is expressed on mature T cells, thymocytes and NKT cells. CD3 is associated with the T cell receptor (TCR) and induces the signaling cascade for effector functions of the T cell.
Activation and proliferation of T cells can be induced by interaction of the T cell receptor (TCR) with peptide-MHC complexes expressed on the surface of antigen presenting cells (APC). T cell activation can also be achieved by agonistic stimulation with the CD3 antibody binding to the TCR complex.
Applications
The antibody is suitable for
ex vivo
T cell activation and expansion and is already established in a variety of clinical protocols for
ex vivo
T cell stimulation. For example, the transduction of T cells with viral vectors requires the previous activation, which can be achieved by stimulation with CD3 antibody
1,2
. Furthermore, T cell subsets, such as tumor infiltrating lymphocytes (TILs) can be expanded
3
, or T cells polyclonally activated by CD3 stimulation.
The CD3 antibody can be combined with CD28 antibody, which gives an additional costimulatory stimulus
4
.
Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
Selected references
Pule, M. A. et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11): 1264-1270
Ciceri, F. et al. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 10(5): 489-500
Dudley, M. E. et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10): 2346-2357
Lamers et al. (2002) Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 9(7): 613-623
MACS GMP T Cell TransAct